130 related articles for article (PubMed ID: 10501918)
1. Glutamyl hydrolase and the multitargeted antifolate LY231514.
Rhee MS; Ryan TJ; Galivan J
Cancer Chemother Pharmacol; 1999; 44(5):427-32. PubMed ID: 10501918
[TBL] [Abstract][Full Text] [Related]
2. Glutamyl hydrolase: properties and pharmacologic impact.
Galivan J; Ryan T; Rhee M; Yao R; Chave K
Semin Oncol; 1999 Apr; 26(2 Suppl 6):33-7. PubMed ID: 10598552
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
Zhao R; Babani S; Gao F; Liu L; Goldman ID
Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
[TBL] [Abstract][Full Text] [Related]
4. Effects of gamma-glutamyl hydrolase on folyl and antifolylpolyglutamates in cultured H35 hepatoma cells.
Yao R; Rhee MS; Galivan J
Mol Pharmacol; 1995 Sep; 48(3):505-11. PubMed ID: 7565632
[TBL] [Abstract][Full Text] [Related]
5. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
6. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
7. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
[TBL] [Abstract][Full Text] [Related]
8. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
9. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
Schultz RM; Patel VF; Worzalla JF; Shih C
Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity.
Rhee MS; Wang Y; Nair MG; Galivan J
Cancer Res; 1993 May; 53(10 Suppl):2227-30. PubMed ID: 7683570
[TBL] [Abstract][Full Text] [Related]
11. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.
Britten CD; Izbicka E; Hilsenbeck S; Lawrence R; Davidson K; Cerna C; Gomez L; Rowinsky EK; Weitman S; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(2):105-10. PubMed ID: 10412943
[TBL] [Abstract][Full Text] [Related]
12. Overview of phase I trials of multitargeted antifolate (MTA, LY231514).
Rinaldi DA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):82-8. PubMed ID: 10598560
[TBL] [Abstract][Full Text] [Related]
13. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Teicher BA; Chen V; Shih C; Menon K; Forler PA; Phares VG; Amsrud T
Clin Cancer Res; 2000 Mar; 6(3):1016-23. PubMed ID: 10741729
[TBL] [Abstract][Full Text] [Related]
14. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
Semin Oncol; 1999 Apr; 26(2 Suppl 6):48-54. PubMed ID: 10598555
[TBL] [Abstract][Full Text] [Related]
15. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
16. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.
Worzalla JF; Shih C; Schultz RM
Anticancer Res; 1998; 18(5A):3235-9. PubMed ID: 9858888
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and disposition of the antifolate LY231514 in mice and dogs.
Woodland JM; Barnett CJ; Dorman DE; Gruber JM; Shih C; Spangle LA; Wilson TM; Ehlhardt WJ
Drug Metab Dispos; 1997 Jun; 25(6):693-700. PubMed ID: 9193870
[TBL] [Abstract][Full Text] [Related]
18. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
Pestieau SR; Stuart OA; Sugarbaker PH
Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
[TBL] [Abstract][Full Text] [Related]
19. [LY231514. A multitargeted antifolate (MTA)].
Lansiaux A; Degardin M; Bailly C
Bull Cancer; 1999 Sep; 86(9):727-31. PubMed ID: 10519965
[No Abstract] [Full Text] [Related]
20. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
